23andMe CEO Grilled on Genetic Data Security and Bioweapon Potential

Concerns Over Genetic Data and Bioweapons

• 🎯 23andMe holds the second-largest collection of DNA data, with approximately 14-15 million users, second only to Ancestry DNA.
• ⚠️ A key concern raised is the potential for genetic data to be used by rogue actors or nation-states to create targeted bioweapons.
• 🔬 The scientific possibility of creating bioweapons targeting specific ethnicities or geographic locations based on genetic data is acknowledged, provided a large, global dataset is available.

23andMe's Bankruptcy and Data Security Commitments

• 🛡️ During the bankruptcy process, 23andMe has committed to not selling its data to foreign adversaries, including specific countries like China, Russia, Iran, Venezuela, and North Korea.
• 🤝 The two final bidders in the auction process, TTIM Research Institute and Regeneron, are both American enterprises.
• ⚖️ The ownership of genetic data by individuals is discussed, with the acknowledgment that the likelihood of users actively requesting data deletion is very low.

National Security and Foreign Investment

• 🌍 Questions were raised about whether the board considered the national security implications of sharing genetic data with foreign research institutions, particularly those in China.
• 🚫 It was stated that no foreign actor had attempted to purchase data for research purposes.
• 🇨🇳 Regarding Wui Healthcare Ventures, an investor with ties to the CCP and PLA, it was clarified they were a $10 million investor in a $150 million round and had no board seat or access to information.

Business Model Comparison: 23andMe vs. Ancestry DNA

• 🧬 Ancestry DNA's success is attributed to its focus on providing customers with their ancestry history and historical records.
• 💡 23andMe's mission has been to help people understand and benefit from the human genome, primarily for advancing human health through genetic research.
• 📈 A point of contention was whether 23andMe's expansion into health-related genetic testing, compared to Ancestry DNA's focus, contributed to its current business challenges.